# SHS Capital

> SHS Capital is a VC fund in Tübingen backing Health Care and Medical Device. See 44 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Tübingen, Germany
- Total investments: 44
- Last investment: Mar 2026
- Lead investor: 57%
- Last fund: Jul 2022
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/shs-gesellschaft-fuer-beteiligungsmanagement-mbh
- Website: http://www.shs-capital.eu

SHS Capital is a VC fund in Tübingen focused on Health Care and Medical Device. SHS is an independent private equity company. Their focus is on investments in the MedTech, Life Sciences, Diagnostics, and Digital Health sectors.

## Contacts

5 contacts available for SHS Capital. Shizune tracks 11 team members at SHS Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/shs-gesellschaft-fr-beteiligungsmanagement-mbh?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $4.9M–$60M |
| Series C | $6.6M–$14M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 17 | 39% |
| Medical Device | 14 | 32% |
| Medical | 12 | 27% |
| Manufacturing | 11 | 25% |
| Biotechnology | 10 | 23% |

37 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 15 | 34% |
| Series B | 5 | 11% |
| Series C | 5 | 11% |
| Series A | 4 | 9% |
| Venture - Series Unknown | 4 | 9% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 14 | 32% |
| Switzerland | 7 | 16% |
| France | 2 | 5% |
| Austria | 2 | 5% |
| The Netherlands | 2 | 5% |

9 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andre Zimmermann | Partner | 2 | https://shizune.co/investors/profile/andre-zimmermann |
| Sascha Alilovic | Partner | 5 | https://shizune.co/investors/profile/sascha-alilovic |
| Bernhard Schirmers | Managing partner | 2 | https://shizune.co/investors/profile/bernhard-schirmers |
| David Wehner | Senior Investment manager | 1 | https://shizune.co/investors/profile/david-wehner-3 |
| Federico Bursgens | Limited Partner | 0 | https://shizune.co/investors/profile/federico-bursgens |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Arzneimittelwerk Warngau | Arzneimittelwerk Warngau develops and markets drug delivery systems. Its portfolio includes active ingredient/biodegradable implants and transdermal systems in the areas of oncology, pain therapy, and neurology. It focuses on transdermal passive and microchip controlled patches, as well as subcutaneous biodegradable implants. WilfriedFischer founded Arzneimittelwerk Warngau in 2008. It has its headquarters in Warngau in Germany. |  | Secondary Market | Mar 05, 2026 |  |
| Salvia BioElectronics | Salvia BioElectronics develops innovative neuromodulation devices aimed at treating migraines. The company focuses on creating a paper-thin implant that delivers gentle electrical pulses to specific nerves, helping to alleviate migraine symptoms. Salvia BioElectronics is dedicated to advancing its technology through ongoing research and developmentefforts. With recent funding, the company works to bring its migraine therapy to market, offering a new approach to pain management for patients. The emphasis is on improving patient outcomes through effective neuromodulation therapy. | $60.1M | Series B | May 27, 2025 |  |
| Develco Pharma Schweiz | Develco Pharma Schweiz is pharmaceutical manufacturing company produce formulations of drugs, health care, medicine. | $11M |  | Oct 07, 2024 |  |
| MESI Medical | We help clinicians provide better medical assessment in less time! The MESI mTABLET is an FDA/CE marked predictive medical assessment platform for ambulatory healthcare with extensive AI and marketplace capabilities. | $19.7M | Venture - Series Unknown | Jun 22, 2023 |  |
| Simulands | Simulands improve patient outcomes through simulation-based medical training. Simulands solutions are more practical, cost effective, and ethical versus traditional methods. | $10.6M | Seed | Mar 02, 2023 |  |
| Dr.Dropin | Dr.Dropin an accessible and modern private health service that offers the vast majority of medical services at a fixed price. | $20.8M | Venture - Series Unknown | Apr 21, 2022 |  |
| PathoQuest | PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $15.9M | Series B | Nov 09, 2021 |  |
| PathoQuest | PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $17.4M | Series B | Nov 09, 2021 |  |
| Incision | Incision is a developer of a medical education platform built to offer a standardized method of how to perform a procedure in practical steps and sub-steps. |  | Series A | May 27, 2021 |  |
| Incision | Incision is a developer of a medical education platform built to offer a standardized method of how to perform a procedure in practical steps and sub-steps. | $5.5M | Series A | May 24, 2021 |  |

10 of 44 investments shown.

## Co-investors
- [KfW](https://shizune.co/investors/profile/kfw) — VC Fund, 7 deals together
- [Delta Partners](https://shizune.co/investors/profile/delta-partners) — VC Fund, 4 deals together
- [Earlybird Venture Capital](https://shizune.co/investors/profile/earlybird-venture-capital) — VC Fund, 4 deals together
- [UVC Partners](https://shizune.co/investors/profile/uvc-partners) — VC Fund, 4 deals together
- [Bayern Kapital](https://shizune.co/investors/profile/bayern-kapital) — VC Fund, 3 deals together
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [Fil Rouge Capital (FRC)](https://shizune.co/investors/profile/fil-rouge-capital-frc) — VC Fund
- [LAUNCHub Ventures](https://shizune.co/investors/profile/launchub) — VC Fund
- [Silicon Gardens](https://shizune.co/investors/profile/silicon-gardens) — VC Fund

## Featured in investor lists
- [Medical Investors in Germany](https://shizune.co/investors/medical-investors-germany)
- [Medical VC Funds in Finland](https://shizune.co/investors/medical-vc-funds-finland)
- [Medical Device Investors in Austria](https://shizune.co/investors/medical-device-investors-austria)
- [Medical Device VC Funds in Austria](https://shizune.co/investors/medical-device-vc-funds-austria)
- [Medical Device Investors in Switzerland](https://shizune.co/investors/medical-device-investors-switzerland)
- [Health Care VC Funds in Austria](https://shizune.co/investors/health-care-vc-funds-austria)

## FAQ

### What does SHS Capital invest in?

SHS Capital invests primarily in Health Care, Medical Device and Medical startups, most often at Funding Round and Series B stage. Most of the 44 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is SHS Capital's check size?

SHS Capital typically joins rounds of $4.9M–$60M at Series B and $6.6M–$14M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SHS Capital participates in.

### How do I contact SHS Capital?

Public channels for SHS Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at SHS Capital?

The team at SHS Capital includes Andre Zimmermann (Partner), Sascha Alilovic (Partner) and Bernhard Schirmers (Managing partner), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co